Researchers Demonstrate Effective Treatment and Outstanding Cosmetic Outcome of Elekta's Electronic Brachytherapy for Skin Cancer

VALENCIA, Spain, June 17, 2015 /PRNewswire/ --

Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya^® electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya.

The paper, "Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma,"^[1]  is based on data from an ongoing, prospective clinical study.

The investigators conclude that Esteya electronic brachytherapy is a good treatment alternative for patients who are unsuitable for surgery, in addition to those who have declined surgery, have multiple lesions and for whom electronic brachytherapy might improve cosmetic outcome.

About Esteya 

Elekta's Esteyaelectronic brachytherapy is a new, high-precision treatment solution for treating skin cancer. Esteya mimics high dose rate (HDR) brachytherapy by bringing a miniaturized x-ray source very close to the cancerous site, enabling the local application of radiation for effective treatment. With this direct delivery, Esteya can concentrate more therapeutic radiation to the disease target and minimize radiation to the surrounding tissues and organs. The compact design of the system, combined with high mobility, allows the treatment to occur virtually anywhere patients are seen.

About Elekta 

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: http://www.elekta.com.

1. J Contemp Brachytherapy 2015; 7, 3: DOI: 10.5114/jcb.2015.52140. http://www.termedia.pl/Efficacy-and-safety-of-electronic-brachytherapy-for-superficial-and-nodular-basal-cell-carcinoma,54,25225,1,1.html

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31-653-561-242, e-mail: [email protected]
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1-770-670-2524, e-mail: [email protected]
Time zone: ET: Eastern Time

SOURCE Elekta